Constraint Finder
Pick an organ and a fraction count to see commonly used dose constraints — each one quoted from a published protocol and linked to the study behind it.
Try
| Organ | Schedule | Constraint | Source | Table |
|---|---|---|---|---|
| Anus / Anal Canal | 45–50.4 Gy / 25–28 fx + boost Composite plan (SIB or sequential boost) | D50% ≤40 Gy, D0.03 cc ≤50 Gy | NRG vulva RT template | Vulva |
| Bladder | 25 Gy / 5 fx Short course | D45% <21 Gy | RCR rectal IMRT guidance | Rectum |
| Bladder | 36.25 Gy / 5 fx To PTV (40 Gy to CTV) | V37 Gy ≤5 cc (ideal), ≤10 cc (acceptable) | PACE-B | Prostate SBRT |
| Bladder | 36.25 Gy / 5 fx To PTV (40 Gy to CTV) | V18.1 Gy ≤40% | King 2012 | Prostate SBRT |
| Bladder | 52.5 Gy / 20 fx 2.63 Gy per fraction | V40 Gy <80% | RADICALS-HD | Post-Prostatectomy (Prostate Bed) |
| Bladder | 60 Gy / 20 fx Moderate hypofractionation | V48.6 Gy <25% | CHHiP (Dearnaley 2016), CHHiP PROs (Wilkins 2015) | Definitive Prostate IMRT/VMAT |
| Bladder | 60 Gy / 20 fx Nodes 44 Gy | V48.6 Gy <25% | CHHiP (Dearnaley 2016), CHHiP PROs (Wilkins 2015) | Prostate + Pelvic Nodes |
| Bladder | 52.5 Gy / 20 fx 2.63 Gy per fraction | V48 Gy <50% | RADICALS-HD | Post-Prostatectomy (Prostate Bed) |
| Bladder | 60 Gy / 20 fx Moderate hypofractionation | V60 Gy <5% | CHHiP (Dearnaley 2016), CHHiP PROs (Wilkins 2015) | Definitive Prostate IMRT/VMAT |
| Bladder | 60 Gy / 20 fx Nodes 44 Gy | V60 Gy <5% | CHHiP (Dearnaley 2016), CHHiP PROs (Wilkins 2015) | Prostate + Pelvic Nodes |
| Bladder | 45–50.4 Gy / 25–28 fx Long course | V40 Gy <40%, V45 Gy <15% | RTOG 0822 | Rectum |
| Bladder | 45–50.4 Gy / 25–28 fx Pelvis ± nodal boost | D50% ≤45 Gy, D0.03 cc ≤50 Gy | NRG cervix RT template | Cervix — Definitive Chemoradiation |
| Bladder | 45–50.4 Gy / 25–28 fx Post-operative pelvis | V45 Gy ≤35% | NRG endometrial RT template | Endometrium & Cervix — Post-operative |
| Bladder | 45–50.4 Gy / 25–28 fx + boost Composite plan (SIB or sequential boost) | D35% ≤45 Gy, D0.03 cc ≤60 Gy | NRG vulva RT template | Vulva |
| Bladder | 68 Gy / 25 fx Nodes 45–50 Gy | V50 Gy <25% | POP-RT (toxicity) | Prostate + Pelvic Nodes |
| Bladder | 45–50.4 Gy / 25–28 fx Long course | Max <50 Gy | RTOG 0822 | Rectum |
| Bladder | 45–50.4 Gy / 25–28 fx Pelvis ± nodal boost | V40 Gy <60%, V30 Gy <80% | EMBRACE II | Cervix — Definitive Chemoradiation |
| Bladder | 68 Gy / 25 fx Nodes 45–50 Gy | V60 Gy <15% | POP-RT (toxicity) | Prostate + Pelvic Nodes |
| Bladder | 50.4–54 Gy / 28–30 fx Dose-painted IMRT | V35 Gy <50%, V40 Gy <35%, V50 Gy <5% | RTOG 0529, NRG anal RT template | Anal Canal |
| Bladder | 70 Gy / 28 fx Moderate hypofractionation | V70 Gy ≤15% | ASTRO DVH Compendium 2026 | Definitive Prostate IMRT/VMAT |
| Bladder | 70 Gy / 28 fx Moderate hypofractionation | V65 Gy ≤25% | ASTRO DVH Compendium 2026 | Definitive Prostate IMRT/VMAT |
| Bladder | 70 Gy / 28 fx Moderate hypofractionation | V40 Gy ≤65% | ASTRO DVH Compendium 2026 | Definitive Prostate IMRT/VMAT |
| Bladder | 64–66 Gy / 32–33 fx 2 Gy per fraction | V65 Gy <50% | ENZARAD protocol, QUANTEC | Post-Prostatectomy (Prostate Bed) |
| Bladder | 64–66 Gy / 32–33 fx 2 Gy per fraction | V70 Gy <35% | ENZARAD protocol, QUANTEC | Post-Prostatectomy (Prostate Bed) |
| Bladder | 78–80 Gy / 39–40 fx Conventional | V65 Gy <50% | ENZARAD protocol, QUANTEC | Definitive Prostate IMRT/VMAT |
| Bladder | 78–80 Gy / 39–40 fx Nodes 54–60 Gy | V65 Gy <50% | ENZARAD protocol, QUANTEC | Prostate + Pelvic Nodes |
| Bladder | 78–80 Gy / 39–40 fx Conventional | V70 Gy <35% | ENZARAD protocol, QUANTEC | Definitive Prostate IMRT/VMAT |
| Bladder | 78–80 Gy / 39–40 fx Nodes 54–60 Gy | V70 Gy <35% | ENZARAD protocol, QUANTEC | Prostate + Pelvic Nodes |
| Brachial Plexus | 30–34 Gy / 1 fx Peripheral | Max dose <15 Gy | TROG SAFRON II | Lung SBRT |
| Brachial Plexus | 54 Gy / 3 fx Peripheral | Max dose <24 Gy | TROG CHISEL | Lung SBRT |
| Brachial Plexus | 50 Gy / 5 fx Central | Max dose 32 Gy | RTOG 0813 | Lung SBRT |
| Brachial Plexus | 50 Gy / 5 fx Central | D3 cc <30 Gy | RTOG 0813 | Lung SBRT |
| Brachial Plexus | 60 Gy / 30 fx ± concurrent chemotherapy | Max dose ≤66 Gy (EQD2) | eviQ 1871 | Conventional / Hypofractionated Lung RT |
| Brachial Plexus | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Max ≤66 Gy | Timmerman 2022 | Head & Neck Planning Essentials |
| Brain | 1 fx 15–24 Gy | V12 Gy 5, 10, >15 cc: about 10%, 15%, 20% risk of symptomatic necrosis | HyTEC brain (Milano 2021) | Stereotactic Radiosurgery (SRS) |
| Brain | 3 fx 24–30 Gy | V20 Gy <20 cc | HyTEC brain (Milano 2021) | Stereotactic Radiosurgery (SRS) |
| Brain | 5 fx 25–35 Gy | V24 Gy <20 cc | HyTEC brain (Milano 2021) | Stereotactic Radiosurgery (SRS) |
| Brain | 60 Gy / 30 fx Standard course | Limit hotspots >60 Gy | eviQ 409 | High-Grade Glioma |
| Brainstem | 1 fx 15–24 Gy | D0.035 cc ≤10 Gy (ideal), ≤15 Gy (acceptable) | UK SABR consensus 2022 | Stereotactic Radiosurgery (SRS) |
| Brainstem | 3 fx 24–30 Gy | D0.035 cc ≤18 Gy (ideal), ≤23.1 Gy (acceptable) | UK SABR consensus 2022 | Stereotactic Radiosurgery (SRS) |
| Brainstem | 5 fx 25–35 Gy | D0.035 cc ≤23 Gy (ideal), ≤31 Gy (acceptable) | UK SABR consensus 2022 | Stereotactic Radiosurgery (SRS) |
| Brainstem | 40.05 Gy / 15 fx Short course; also 34 Gy / 10 fx and 25 Gy / 5 fx | Max <100% of prescription | eviQ 410 | High-Grade Glioma |
| Brainstem | 60 Gy / 30 fx Standard course | Max <54 Gy | QUANTEC brainstem | High-Grade Glioma |
| Brainstem | 60 Gy / 30 fx Standard course | PRV max <60 Gy | eviQ 409 | High-Grade Glioma |
| Brainstem | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Max ≤54 Gy | QUANTEC brainstem, Emami 2013, Scoccianti 2015 | Head & Neck Planning Essentials |
| Brainstem | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | PRV max ≤60 Gy | eviQ 5049 | Head & Neck Planning Essentials |
| Carotid Arteries | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | As low as reasonably achievable | eviQ 5049 | Head & Neck Planning Essentials |
| Central Hepatobiliary Tract | 42–54 Gy / 3 fx Liver metastases | D21 cc <33.8 Gy, D24 cc <32 Gy | LARK (TROG 17.03) | Liver SBRT |
| Central Hepatobiliary Tract | 27.5–60 Gy / 5 fx HCC or metastases | Mean <19 Gy | LARK (TROG 17.03) | Liver SBRT |
| Central Hepatobiliary Tract | 27.5–60 Gy / 5 fx HCC or metastases | D21 cc <40 Gy, D24 cc <37.7 Gy | LARK (TROG 17.03) | Liver SBRT |
| Cervical Esophagus | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Mean <35 Gy | RTOG 0920 | Head & Neck Planning Essentials |
| Chest Wall / Ribs | 30–34 Gy / 1 fx Peripheral | Avoid the 26 Gy isodose through the full thickness of the chest wall | TROG SAFRON II | Lung SBRT |
| Chest Wall / Ribs | 42–54 Gy / 3 fx Liver metastases | D0.5 cc ≤37 Gy | LARK (TROG 17.03) | Liver SBRT |
| Chest Wall / Ribs | 54 Gy / 3 fx Peripheral | D30 cc <30 Gy (D70 cc <30 Gy acceptable if not achievable) | TROG SAFRON II | Lung SBRT |
| Chest Wall / Ribs | 42–54 Gy / 3 fx Liver metastases | V30 Gy <30 cc | Dunlap 2010 | Liver SBRT |
| Chest Wall / Ribs | 27.5–60 Gy / 5 fx HCC or metastases | D0.5 cc ≤39 Gy | LARK (TROG 17.03) | Liver SBRT |
| Chest Wall / Ribs | 50 Gy / 5 fx Central | D30 cc <30 Gy | Lo 2013 | Lung SBRT |
| Chest Wall / Ribs | 27.5–60 Gy / 5 fx HCC or metastases | V30 Gy <30 cc | Dunlap 2010 | Liver SBRT |
| Cochlea | 1 fx 15–24 Gy | Mean <4 Gy (ideal) | ACOUNEU (Marchetti 2025) | Stereotactic Radiosurgery (SRS) |
| Cochlea | 3 fx 24–30 Gy | Mean <7 Gy (ideal) | ACOUNEU (Marchetti 2025) | Stereotactic Radiosurgery (SRS) |
| Cochlea | 5 fx 25–35 Gy | D0.035 cc ≤22 Gy (ideal) | Timmerman 2022 | Stereotactic Radiosurgery (SRS) |
| Cochlea | 60 Gy / 30 fx Standard course | Mean <45 Gy | QUANTEC hearing | High-Grade Glioma |
| Cochlea | 60 Gy / 30 fx Standard course | V55 Gy <5% | eviQ 409 | High-Grade Glioma |
| Cochlea | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Mean ≤45 Gy | Emami 2013, Scoccianti 2015, QUANTEC hearing | Head & Neck Planning Essentials |
| Cochlea | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | V55 Gy <5% | RTOG 0615 | Head & Neck Planning Essentials |
| Common Bile Duct | 42–54 Gy / 3 fx Liver metastases | D0.1 cc ≤50 Gy | UK SABR consensus 2022 | Liver SBRT |
| Common Bile Duct | 27.5–60 Gy / 5 fx HCC or metastases | D0.1 cc ≤50 Gy | UK SABR consensus 2022 | Liver SBRT |
| Contralateral Breast | All schedules 40.05 Gy/15 fx · 30 Gy/5 fx · 26 Gy/5 fx | Dmax ≤3% (ideal), ≤5% (acceptable) | ASTRO PBI 2023 | Partial Breast |
| Contralateral Breast | 40.05 Gy / 15 fx or 42.56 Gy / 16 fx | Mean <1.5 Gy (mandatory) | IMPORT HIGH | Whole Breast |
| Contralateral Breast | 40.05 Gy / 15 fx or 42.56 Gy / 16 fx | Mean <0.5 Gy (optimal) | IMPORT HIGH | Whole Breast |
| Contralateral Breast | 45–50 Gy / 25 fx 1.8–2 Gy per fraction | V3 Gy <10% (ideal) | NSABP B-51 | Regional Nodal Irradiation |
| Contralateral Breast | 50 Gy / 25 fx | V3 Gy <10% (ideal) | NSABP B-51 | Post-Mastectomy Chest Wall |
| Contralateral Breast | 45–50 Gy / 25 fx 1.8–2 Gy per fraction | V5 Gy <10% (acceptable) | NSABP B-51 | Regional Nodal Irradiation |
| Contralateral Breast | 50 Gy / 25 fx | V5 Gy <10% (acceptable) | NSABP B-51 | Post-Mastectomy Chest Wall |
| Contralateral Lung | All schedules 40.05 Gy/15 fx · 30 Gy/5 fx · 26 Gy/5 fx | V10% ≤5% (ideal) | ASTRO PBI 2023 | Partial Breast |
| Contralateral Lung | 40.05 Gy / 15 fx or 42.56 Gy / 16 fx | V5 Gy <10% | eviQ 3650 | Whole Breast |
| Contralateral Lung | All schedules 40.05 Gy/15 fx · 30 Gy/5 fx · 26 Gy/5 fx | V5% ≤15% (acceptable) | ASTRO PBI 2023 | Partial Breast |
| Contralateral Lung | 45–50 Gy / 25 fx 1.8–2 Gy per fraction | V5 Gy <10% | eviQ 1924 | Regional Nodal Irradiation |
| Contralateral Lung | 50 Gy / 25 fx | V5 Gy <10% | eviQ 1925 | Post-Mastectomy Chest Wall |
| Duodenum | 42–54 Gy / 3 fx Liver metastases | D0.1 cc ≤22.2 Gy | UK SABR consensus 2022 | Liver SBRT |
| Duodenum | 42–54 Gy / 3 fx Liver metastases | D10 cc ≤11.4 Gy | UK SABR consensus 2022 | Liver SBRT |
| Duodenum | 27.5–60 Gy / 5 fx HCC or metastases | D0.1 cc ≤33 Gy (optimal), ≤35 Gy (mandatory) | UK SABR consensus 2022 | Liver SBRT |
| Duodenum | 27.5–60 Gy / 5 fx HCC or metastases | D10 cc ≤25 Gy | UK SABR consensus 2022 | Liver SBRT |
| Duodenum | 45–50.4 Gy / 25–28 fx Pelvis ± nodal boost | V55 Gy <15 cc | EMBRACE II, Verma 2014 | Cervix — Definitive Chemoradiation |
| Duodenum | 50.4 Gy / 28 fx 45–54 Gy / 25–30 fx | V55 Gy <15 cc | Verma 2014 | Pancreas |
| Duodenum | 50.4 Gy / 28 fx 45–54 Gy / 25–30 fx | D15% <45 Gy | eviQ 3581 | Pancreas |
| Esophagus | 30–34 Gy / 1 fx Peripheral | Max dose <15.4 Gy | TROG SAFRON II | Lung SBRT |
| Esophagus | 42–54 Gy / 3 fx Liver metastases | D0.1 cc ≤25.2 Gy | UK SABR consensus 2022 | Liver SBRT |
| Esophagus | 54 Gy / 3 fx Peripheral | Max dose <27 Gy | TROG CHISEL | Lung SBRT |
| Esophagus | 27.5–60 Gy / 5 fx HCC or metastases | D0.1 cc ≤35 Gy | UK SABR consensus 2022 | Liver SBRT |
| Esophagus | 50 Gy / 5 fx Central | Max dose 52.5 Gy | RTOG 0813 | Lung SBRT |
| Esophagus | 27.5–60 Gy / 5 fx HCC or metastases | D0.5 cc ≤32 Gy | LARK (TROG 17.03) | Liver SBRT |
| Esophagus | 50 Gy / 5 fx Central | D5 cc <27.5 Gy | RTOG 0813 | Lung SBRT |
| Esophagus | 60 Gy / 30 fx ± concurrent chemotherapy | Mean dose <34 Gy | QUANTEC summary | Conventional / Hypofractionated Lung RT |
| Esophagus | 60 Gy / 30 fx ± concurrent chemotherapy | Mean dose ≤28 Gy (concurrent chemo) | Wei 2006 | Conventional / Hypofractionated Lung RT |
| Esophagus | 60 Gy / 30 fx ± concurrent chemotherapy | V60Gy ≤17% (concurrent chemo) | Palma 2013 | Conventional / Hypofractionated Lung RT |
| External Genitalia & Perineum | 50.4–54 Gy / 28–30 fx Dose-painted IMRT | V20 Gy <50%, V30 Gy <35%, V40 Gy <5% | RTOG 0529, NRG anal RT template | Anal Canal |
| Femoral Heads | 36.25 Gy / 5 fx To PTV (40 Gy to CTV) | V14.5 Gy <5% | King 2012 | Prostate SBRT |
| Femoral Heads | 52.5 Gy / 20 fx 2.63 Gy per fraction | V43 Gy <5% | eviQ 4487 | Post-Prostatectomy (Prostate Bed) |
| Femoral Heads | 60 Gy / 20 fx Moderate hypofractionation | V40.8 Gy <50% | CHHiP (Dearnaley 2016), CHHiP PROs (Wilkins 2015) | Definitive Prostate IMRT/VMAT |
| Femoral Heads | 60 Gy / 20 fx Nodes 44 Gy | V40.8 Gy <50% | CHHiP (Dearnaley 2016), CHHiP PROs (Wilkins 2015) | Prostate + Pelvic Nodes |
| Femoral Heads | 45–50.4 Gy / 25–28 fx Long course | V40 Gy <40%, V45 Gy <25% | RTOG 0822 | Rectum |
| Femoral Heads | 45–50.4 Gy / 25–28 fx Pelvis ± nodal boost | D15% ≤30 Gy, D0.03 cc ≤50 Gy | NRG cervix RT template | Cervix — Definitive Chemoradiation |
| Femoral Heads | 45–50.4 Gy / 25–28 fx Post-operative pelvis | D15% ≤30 Gy, D0.03 cc ≤50 Gy | NRG endometrial RT template | Endometrium & Cervix — Post-operative |
| Femoral Heads | 45–50.4 Gy / 25–28 fx + boost Composite plan (SIB or sequential boost) | D15% ≤30 Gy, D5% ≤40 Gy | NRG vulva RT template | Vulva |
| Femoral Heads | 68 Gy / 25 fx Nodes 45–50 Gy | V50 Gy <5% | POP-RT (toxicity) | Prostate + Pelvic Nodes |
| Femoral Heads | 45–50.4 Gy / 25–28 fx Long course | Max <50 Gy | RTOG 0822 | Rectum |
| Femoral Heads | 45–50.4 Gy / 25–28 fx + boost Composite plan (SIB or sequential boost) | D0.03 cc ≤50 Gy | NRG vulva RT template | Vulva |
| Femoral Heads | 50.4–54 Gy / 28–30 fx Dose-painted IMRT | V30 Gy <50%, V40 Gy <35%, V44 Gy <5% | RTOG 0529, NRG anal RT template | Anal Canal |
| Femoral Heads | 70 Gy / 28 fx Moderate hypofractionation | V40 Gy 0% | ASTRO DVH Compendium 2026 | Definitive Prostate IMRT/VMAT |
| Femoral Heads | 64–66 Gy / 32–33 fx 2 Gy per fraction | V50 Gy <5% | ENZARAD protocol | Post-Prostatectomy (Prostate Bed) |
| Femoral Heads | 78–80 Gy / 39–40 fx Conventional | V50 Gy <5% | ENZARAD protocol | Definitive Prostate IMRT/VMAT |
| Femoral Heads | 78–80 Gy / 39–40 fx Nodes 54–60 Gy | V50 Gy <5% | ENZARAD protocol | Prostate + Pelvic Nodes |
| Gallbladder | 27.5–60 Gy / 5 fx HCC or metastases | D0.5 cc ≤55 Gy | LARK (TROG 17.03) | Liver SBRT |
| Globes (Eyes) | 1 fx 15–24 Gy | D0.1 cc ≤8 Gy (ideal) | UK SABR consensus 2022 | Stereotactic Radiosurgery (SRS) |
| Globes (Eyes) | 3 fx 24–30 Gy | D0.035 cc ≤15 Gy (ideal), ≤20 Gy (acceptable) | eviQ 3253 | Stereotactic Radiosurgery (SRS) |
| Globes (Eyes) | 5 fx 25–35 Gy | D0.035 cc ≤22.5 Gy (ideal), ≤25 Gy (acceptable) | eviQ 3253 | Stereotactic Radiosurgery (SRS) |
| Globes (Eyes) | 60 Gy / 30 fx Standard course | Mean <35 Gy, max <50 Gy | eviQ 409 | High-Grade Glioma |
| Globes (Eyes) | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Mean ≤35 Gy, max ≤50 Gy | RTOG 0615 | Head & Neck Planning Essentials |
| Globes (Eyes) | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Anterior globe (cornea, lens, iris): max ≤30 Gy; PRV max ≤35 Gy | DAHANCA 2025 | Head & Neck Planning Essentials |
| Great Vessels | 30–34 Gy / 1 fx Peripheral | Max dose <30 Gy | TROG SAFRON II | Lung SBRT |
| Great Vessels | 54 Gy / 3 fx Peripheral | D0.5 cc <45 Gy | UK SABR Consortium 2019 | Lung SBRT |
| Great Vessels | 50 Gy / 5 fx Central | Max dose 52.5 Gy | RTOG 0813 | Lung SBRT |
| Great Vessels | 50 Gy / 5 fx Central | D10 cc <47 Gy | RTOG 0813 | Lung SBRT |
| Heart / Pericardium | 30–34 Gy / 1 fx Peripheral | Max dose <22 Gy | TROG SAFRON II | Lung SBRT |
| Heart / Pericardium | 30–34 Gy / 1 fx Peripheral | D15 cc <16 Gy | TROG SAFRON II | Lung SBRT |
| Heart / Pericardium | 42–54 Gy / 3 fx Liver metastases | D0.1 cc ≤26 Gy (optimal), ≤30 Gy (mandatory) | UK SABR consensus 2022 | Liver SBRT |
| Heart / Pericardium | 54 Gy / 3 fx Peripheral | Max dose <30 Gy | TROG CHISEL | Lung SBRT |
| Heart / Pericardium | 26 Gy / 5 fx FAST-Forward | V1.5 Gy <30% | FAST-Forward | Post-Mastectomy Chest Wall |
| Heart / Pericardium | 26 Gy / 5 fx FAST-Forward | V1.5 Gy <30% | FAST-Forward | Whole Breast |
| Heart / Pericardium | 27.5–60 Gy / 5 fx HCC or metastases | D0.1 cc ≤38 Gy | UK SABR consensus 2022 | Liver SBRT |
| Heart / Pericardium | 50 Gy / 5 fx Central | Max dose 52.5 Gy | RTOG 0813 | Lung SBRT |
| Heart / Pericardium | 26 Gy / 5 fx FAST-Forward | V7 Gy <5% | FAST-Forward | Post-Mastectomy Chest Wall |
| Heart / Pericardium | 26 Gy / 5 fx FAST-Forward | V7 Gy <5% | FAST-Forward | Whole Breast |
| Heart / Pericardium | 27.5–60 Gy / 5 fx HCC or metastases | D5 cc ≤30 Gy | LARK (TROG 17.03) | Liver SBRT |
| Heart / Pericardium | 50 Gy / 5 fx Central | D15 cc ≤32 Gy | RTOG 0813 | Lung SBRT |
| Heart / Pericardium | 40 Gy / 15 fx | V17 Gy <10% | eviQ 1924 | Regional Nodal Irradiation |
| Heart / Pericardium | All schedules 40.05 Gy/15 fx · 30 Gy/5 fx · 26 Gy/5 fx | Left-sided: mean ≤1.5 Gy (ideal), ≤2 Gy (acceptable) | ASTRO PBI 2023 | Partial Breast |
| Heart / Pericardium | 40.05 Gy / 15 fx or 42.56 Gy / 16 fx | V20 Gy <5% | RTOG 1005 | Whole Breast |
| Heart / Pericardium | All schedules 40.05 Gy/15 fx · 30 Gy/5 fx · 26 Gy/5 fx | Right-sided: mean <0.7 Gy (ideal), <1 Gy (acceptable) | ASTRO PBI 2023 | Partial Breast |
| Heart / Pericardium | 40.05 Gy / 15 fx or 42.56 Gy / 16 fx | Mean <4 Gy | RTOG 1005 | Whole Breast |
| Heart / Pericardium | 41.4 Gy / 23 fx Preoperative | V40 Gy <30% | CROSS, Leong 2005 | Esophagus & GE Junction |
| Heart / Pericardium | 41.4 Gy / 23 fx Preoperative | V30 Gy <46% | QUANTEC heart | Esophagus & GE Junction |
| Heart / Pericardium | 45–50 Gy / 25 fx 1.8–2 Gy per fraction | V25 Gy <10% | QUANTEC heart | Regional Nodal Irradiation |
| Heart / Pericardium | 50 Gy / 25 fx | V20 Gy <5% | RTOG 1005 | Post-Mastectomy Chest Wall |
| Heart / Pericardium | 45–50 Gy / 25 fx 1.8–2 Gy per fraction | Mean <5 Gy | eviQ 1924 | Regional Nodal Irradiation |
| Heart / Pericardium | 50 Gy / 25 fx | Mean <4 Gy | RTOG 1005 | Post-Mastectomy Chest Wall |
| Heart / Pericardium | 50.4 Gy / 28 fx Definitive; also 50 Gy / 25 fx | V40 Gy <30% | CROSS, Leong 2005 | Esophagus & GE Junction |
| Heart / Pericardium | 50.4 Gy / 28 fx 45–54 Gy / 25–30 fx | V40 Gy <30% | CROSS, Leong 2005 | Pancreas |
| Heart / Pericardium | 50.4 Gy / 28 fx Definitive; also 50 Gy / 25 fx | V30 Gy <46% | QUANTEC heart | Esophagus & GE Junction |
| Heart / Pericardium | 60 Gy / 30 fx ± concurrent chemotherapy | Mean heart dose ≤20 Gy | Wang 2017 | Conventional / Hypofractionated Lung RT |
| Heart / Pericardium | 60 Gy / 30 fx ± concurrent chemotherapy | V50 ≤25% | Speirs 2017 | Conventional / Hypofractionated Lung RT |
| Hippocampus | 30 Gy / 10 fx NRG CC001 | D100% ≤9 Gy (per protocol), ≤10 Gy (variation acceptable) | NRG CC001 | Whole Brain — Hippocampal Avoidance |
| Hippocampus | 30 Gy / 10 fx NRG CC001 | Max (0.03 cc) ≤16 Gy (per protocol), ≤17 Gy (variation acceptable) | NRG CC001 | Whole Brain — Hippocampal Avoidance |
| Hippocampus | 60 Gy / 30 fx Standard course | As low as reasonably achievable; mean <5–10 Gy | eviQ 409 | High-Grade Glioma |
| Ipsilateral Lung | 26 Gy / 5 fx FAST-Forward | V8 Gy <15% | FAST-Forward | Post-Mastectomy Chest Wall |
| Ipsilateral Lung | 26 Gy / 5 fx FAST-Forward | V8 Gy <15% | FAST-Forward | Whole Breast |
| Ipsilateral Lung | 40 Gy / 15 fx | V17 Gy <35% (combined plans) | SKAGEN Trial 1 | Regional Nodal Irradiation |
| Ipsilateral Lung | All schedules 40.05 Gy/15 fx · 30 Gy/5 fx · 26 Gy/5 fx | V30% ≤10% (ideal), ≤15% (acceptable) | ASTRO PBI 2023 | Partial Breast |
| Ipsilateral Lung | 40.05 Gy / 15 fx or 42.56 Gy / 16 fx | V16 Gy <15% | RTOG 1005 | Whole Breast |
| Ipsilateral Lung | 40.05 Gy / 15 fx or 42.56 Gy / 16 fx | V4 Gy <50% | RTOG 1005 | Whole Breast |
| Ipsilateral Lung | 45–50 Gy / 25 fx 1.8–2 Gy per fraction | V20 Gy <30% | Yim 2015 | Regional Nodal Irradiation |
| Ipsilateral Lung | 50 Gy / 25 fx | V20 Gy ≤15% (ideal), ≤20% (acceptable) | RTOG 1005 | Post-Mastectomy Chest Wall |
| Ipsilateral Lung | 45–50 Gy / 25 fx 1.8–2 Gy per fraction | V5 Gy <70% | NSABP B-51 | Regional Nodal Irradiation |
| Ipsilateral Lung | 50 Gy / 25 fx | V5 Gy ≤50% (ideal) | RTOG 1005 | Post-Mastectomy Chest Wall |
| Kidneys | 42–54 Gy / 3 fx Liver metastases | Mean ≤8.5 Gy | UK SABR consensus 2022 | Liver SBRT |
| Kidneys | 42–54 Gy / 3 fx Liver metastases | ≥200 cc ≤16 Gy | UK SABR consensus 2022 | Liver SBRT |
| Kidneys | 27.5–60 Gy / 5 fx HCC or metastases | Mean ≤10 Gy | UK SABR consensus 2022 | Liver SBRT |
| Kidneys | 27.5–60 Gy / 5 fx HCC or metastases | ≥200 cc ≤17.5 Gy | UK SABR consensus 2022 | Liver SBRT |
| Kidneys | 41.4 Gy / 23 fx Preoperative | Mean <15 Gy (both kidneys) | QUANTEC summary | Esophagus & GE Junction |
| Kidneys | 41.4 Gy / 23 fx Preoperative | V20 Gy <32% | QUANTEC summary | Esophagus & GE Junction |
| Kidneys | 45–50.4 Gy / 25–28 fx Pelvis ± nodal boost | Mean <15 Gy (aim <10 Gy) | EMBRACE II | Cervix — Definitive Chemoradiation |
| Kidneys | 50.4 Gy / 28 fx Definitive; also 50 Gy / 25 fx | Mean <15 Gy (both kidneys) | QUANTEC summary | Esophagus & GE Junction |
| Kidneys | 50.4 Gy / 28 fx 45–54 Gy / 25–30 fx | Mean <15–18 Gy (both kidneys) | QUANTEC summary | Pancreas |
| Kidneys | 50.4 Gy / 28 fx Definitive; also 50 Gy / 25 fx | V20 Gy <32% | QUANTEC summary | Esophagus & GE Junction |
| Kidneys | 50.4 Gy / 28 fx 45–54 Gy / 25–30 fx | V20 Gy <32% | QUANTEC summary | Pancreas |
| LAD (Left Anterior Descending Artery) | 40 Gy / 15 fx | Mean <10 Gy | DEGRO 2019 | Regional Nodal Irradiation |
| LAD (Left Anterior Descending Artery) | 40.05 Gy / 15 fx or 42.56 Gy / 16 fx | Mean <10 Gy | DEGRO 2019 | Whole Breast |
| LAD (Left Anterior Descending Artery) | 40.05 Gy / 15 fx or 42.56 Gy / 16 fx | Max ≤17 Gy | DBCG HYPO 2021 | Whole Breast |
| LAD (Left Anterior Descending Artery) | 45–50 Gy / 25 fx 1.8–2 Gy per fraction | Mean <10 Gy | DEGRO 2019 | Regional Nodal Irradiation |
| LAD (Left Anterior Descending Artery) | 50 Gy / 25 fx | Mean <10 Gy | DEGRO 2019 | Post-Mastectomy Chest Wall |
| LAD (Left Anterior Descending Artery) | 50 Gy / 25 fx | Max ≤20 Gy | SKAGEN Trial 1 | Post-Mastectomy Chest Wall |
| Large Bowel / Sigmoid | 42–54 Gy / 3 fx Liver metastases | D0.1 cc ≤28.2 Gy | UK SABR consensus 2022 | Liver SBRT |
| Large Bowel / Sigmoid | 27.5–60 Gy / 5 fx HCC or metastases | D0.1 cc ≤38 Gy | UK SABR consensus 2022 | Liver SBRT |
| Large Bowel / Sigmoid | 36.25 Gy / 5 fx To PTV (40 Gy to CTV) | Dmax (0.1 cc) <38 Gy | UK SABR consensus 2022 | Prostate SBRT |
| Large Bowel / Sigmoid | 36.25 Gy / 5 fx To PTV (40 Gy to CTV) | D20 cc <25 Gy (optimal) | AAPM TG-101 | Prostate SBRT |
| Large Bowel / Sigmoid | 68 Gy / 25 fx Nodes 45–50 Gy | V50 Gy <35% | POP-RT (toxicity) | Prostate + Pelvic Nodes |
| Large Bowel / Sigmoid | 68 Gy / 25 fx Nodes 45–50 Gy | V70 Gy <0.1% | POP-RT (toxicity) | Prostate + Pelvic Nodes |
| Large Bowel / Sigmoid | 50.4–54 Gy / 28–30 fx Dose-painted IMRT | Loops V30 Gy <200 cc, V35 Gy <150 cc, V45 Gy <20 cc | RTOG 0529 | Anal Canal |
| Large Bowel / Sigmoid | 70 Gy / 28 fx Moderate hypofractionation | D0.035 cc ≤60 Gy | ASTRO DVH Compendium 2026 | Definitive Prostate IMRT/VMAT |
| Large Bowel / Sigmoid | 70 Gy / 28 fx Moderate hypofractionation | V50 Gy ≤1% | ASTRO DVH Compendium 2026 | Definitive Prostate IMRT/VMAT |
| Large Bowel / Sigmoid | 64–66 Gy / 32–33 fx 2 Gy per fraction | V45 Gy <5% or <20 cc | NCCN Anal Cancer v2.2022 | Post-Prostatectomy (Prostate Bed) |
| Large Bowel / Sigmoid | 64–66 Gy / 32–33 fx 2 Gy per fraction | V35 Gy <35% or 150 cc | NCCN Anal Cancer v2.2022 | Post-Prostatectomy (Prostate Bed) |
| Large Bowel / Sigmoid | 78–80 Gy / 39–40 fx Conventional | V45 Gy <5% or <20 cc | NCCN Anal Cancer v2.2022 | Definitive Prostate IMRT/VMAT |
| Large Bowel / Sigmoid | 78–80 Gy / 39–40 fx Nodes 54–60 Gy | V45 Gy <5% or <20 cc | NCCN Anal Cancer v2.2022 | Prostate + Pelvic Nodes |
| Large Bowel / Sigmoid | 78–80 Gy / 39–40 fx Conventional | V35 Gy <35% or 150 cc | NCCN Anal Cancer v2.2022 | Definitive Prostate IMRT/VMAT |
| Large Bowel / Sigmoid | 78–80 Gy / 39–40 fx Nodes 54–60 Gy | V35 Gy <35% or 150 cc | NCCN Anal Cancer v2.2022 | Prostate + Pelvic Nodes |
| Larynx | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Mean ≤45 Gy | RTOG 0615 | Head & Neck Planning Essentials |
| Lens | 1 fx 15–24 Gy | As low as reasonably achievable | eviQ 3253 | Stereotactic Radiosurgery (SRS) |
| Lens | 3 fx 24–30 Gy | As low as reasonably achievable | eviQ 3253 | Stereotactic Radiosurgery (SRS) |
| Lens | 5 fx 25–35 Gy | As low as reasonably achievable | eviQ 3253 | Stereotactic Radiosurgery (SRS) |
| Lens | 30 Gy / 10 fx NRG CC001 | Max ≤5 Gy (ideal) | eviQ 3882 | Whole Brain — Hippocampal Avoidance |
| Lens | 30 Gy / 10 fx or 20 Gy / 5 fx | Max ≤6 Gy (ideal) | eviQ 1251 | Whole Brain — Palliative |
| Lens | 40.05 Gy / 15 fx Short course; also 34 Gy / 10 fx and 25 Gy / 5 fx | Max <10 Gy | Scoccianti 2015 | High-Grade Glioma |
| Lens | 60 Gy / 30 fx Standard course | Max <10 Gy (ideal) | Scoccianti 2015 | High-Grade Glioma |
| Lens | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | D0.03 cc ≤6 Gy (ideal), ≤15 Gy (acceptable) | Lee 2019 NPC guideline | Head & Neck Planning Essentials |
| Lips | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Mean <20 Gy | RTOG 0920 | Head & Neck Planning Essentials |
| Lips | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Max <30 Gy (non-oral cavity), <50 Gy (oral cavity) | RTOG 0920 | Head & Neck Planning Essentials |
| Liver | 42–54 Gy / 3 fx Liver metastases | Mean ≤13 Gy (optimal), ≤15 Gy (mandatory) | UK SABR consensus 2022 | Liver SBRT |
| Liver | 42–54 Gy / 3 fx Liver metastases | ≥700 cc of liver <15 Gy | LARK (TROG 17.03) | Liver SBRT |
| Liver | 27.5–60 Gy / 5 fx HCC or metastases | Mean ≤13 Gy (optimal), ≤15.2 Gy (mandatory) | UK SABR consensus 2022 | Liver SBRT |
| Liver | 27.5–60 Gy / 5 fx HCC or metastases | ≥700 cc of liver <15 Gy | LARK (TROG 17.03) | Liver SBRT |
| Liver | 27.5–60 Gy / 5 fx HCC or metastases | HCC: mean ≤13 Gy (50 Gy) to ≤17 Gy (27.5 Gy) | LARK (TROG 17.03) | Liver SBRT |
| Liver | 41.4 Gy / 23 fx Preoperative | Mean ≤28–30 Gy | eviQ 1861 | Esophagus & GE Junction |
| Liver | 41.4 Gy / 23 fx Preoperative | V30 Gy <30% | eviQ 1861 | Esophagus & GE Junction |
| Liver | 50.4 Gy / 28 fx Definitive; also 50 Gy / 25 fx | Mean ≤28–30 Gy | eviQ 1865 | Esophagus & GE Junction |
| Liver | 50.4 Gy / 28 fx 45–54 Gy / 25–30 fx | Mean <28 Gy | eviQ 3581 | Pancreas |
| Liver | 50.4 Gy / 28 fx Definitive; also 50 Gy / 25 fx | V30 Gy <30% | eviQ 1865 | Esophagus & GE Junction |
| Liver | 50.4 Gy / 28 fx 45–54 Gy / 25–30 fx | V30 Gy <30% | eviQ 3581 | Pancreas |
| Lungs | 30–34 Gy / 1 fx Peripheral | V20 <10% | UK SABR consensus 2022 | Lung SBRT |
| Lungs | 30–34 Gy / 1 fx Peripheral | Mean ≤8 Gy (mandatory), ≤6 Gy (optimal) | UK SABR consensus 2022 | Lung SBRT |
| Lungs | 54 Gy / 3 fx Peripheral | V20 <10% | UK SABR consensus 2022 | Lung SBRT |
| Lungs | 54 Gy / 3 fx Peripheral | Mean ≤8 Gy (mandatory), ≤6 Gy (optimal) | UK SABR consensus 2022 | Lung SBRT |
| Lungs | 50 Gy / 5 fx Central | V20 <10% | UK SABR consensus 2022 | Lung SBRT |
| Lungs | 50 Gy / 5 fx Central | Mean ≤8 Gy (mandatory), ≤6 Gy (optimal) | UK SABR consensus 2022 | Lung SBRT |
| Lungs | 41.4 Gy / 23 fx Preoperative | V20 Gy <20% | eviQ 1861 | Esophagus & GE Junction |
| Lungs | 41.4 Gy / 23 fx Preoperative | Mean <15 Gy | Asakura 2010 | Esophagus & GE Junction |
| Lungs | 50.4 Gy / 28 fx Definitive; also 50 Gy / 25 fx | V20 Gy <30% | QUANTEC summary | Esophagus & GE Junction |
| Lungs | 50.4 Gy / 28 fx Definitive; also 50 Gy / 25 fx | Mean <20 Gy | QUANTEC summary | Esophagus & GE Junction |
| Lungs | 60 Gy / 30 fx ± concurrent chemotherapy | Mean lung dose ≤20 Gy | QUANTEC lung | Conventional / Hypofractionated Lung RT |
| Lungs | 60 Gy / 30 fx ± concurrent chemotherapy | V20Gy ≤35% | QUANTEC lung | Conventional / Hypofractionated Lung RT |
| Mandible | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Avoid hotspots within the mandible | RTOG 0920 | Head & Neck Planning Essentials |
| Mandible | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | V60 Gy <14% | Kubota 2021 | Head & Neck Planning Essentials |
| Optic Chiasm & Optic Nerves | 1 fx 15–24 Gy | D0.035 cc ≤8 Gy (ideal), ≤10 Gy (acceptable) | UK SABR consensus 2022 | Stereotactic Radiosurgery (SRS) |
| Optic Chiasm & Optic Nerves | 3 fx 24–30 Gy | D0.035 cc ≤15 Gy (ideal), ≤20 Gy (acceptable) | UK SABR consensus 2022 | Stereotactic Radiosurgery (SRS) |
| Optic Chiasm & Optic Nerves | 5 fx 25–35 Gy | D0.035 cc ≤22.5 Gy (ideal), ≤25 Gy (mandatory) | UK SABR consensus 2022 | Stereotactic Radiosurgery (SRS) |
| Optic Chiasm & Optic Nerves | 30 Gy / 10 fx NRG CC001 | Max (0.03 cc) ≤30 Gy (per protocol), ≤37.5 Gy (variation acceptable) | NRG CC001 | Whole Brain — Hippocampal Avoidance |
| Optic Chiasm & Optic Nerves | 40.05 Gy / 15 fx Short course; also 34 Gy / 10 fx and 25 Gy / 5 fx | Max <100% of prescription | eviQ 410 | High-Grade Glioma |
| Optic Chiasm & Optic Nerves | 60 Gy / 30 fx Standard course | Max <54 Gy | Scoccianti 2015 | High-Grade Glioma |
| Optic Chiasm & Optic Nerves | 60 Gy / 30 fx Standard course | PRV max <60 Gy | eviQ 409 | High-Grade Glioma |
| Optic Chiasm & Optic Nerves | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Max ≤54 Gy | Scoccianti 2015 | Head & Neck Planning Essentials |
| Optic Chiasm & Optic Nerves | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | PRV max ≤60 Gy | eviQ 5049 | Head & Neck Planning Essentials |
| Oral Cavity | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Non-oral cavity cancers: mean <30 Gy | RTOG 0920 | Head & Neck Planning Essentials |
| Oral Cavity | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Oral cavity cancers: mean <50 Gy | RTOG 0920 | Head & Neck Planning Essentials |
| Parotid Glands | 30 Gy / 10 fx or 20 Gy / 5 fx | As low as reasonably achievable | eviQ 1251 | Whole Brain — Palliative |
| Parotid Glands | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Mean ≤26 Gy (at least one gland) | Timmerman 2022, RTOG 0920, Eisbruch 1999, GORTEC 2004-03 | Head & Neck Planning Essentials |
| Pelvic Bone Marrow | 45–50.4 Gy / 25–28 fx Pelvis ± nodal boost | Mean ≤27 Gy | NRG cervix RT template | Cervix — Definitive Chemoradiation |
| Pelvic Bone Marrow | 45–50.4 Gy / 25–28 fx Post-operative pelvis | V10 Gy ≤90%, V40 Gy ≤37% | NRG endometrial RT template | Endometrium & Cervix — Post-operative |
| Pelvic Bone Marrow | 45–50.4 Gy / 25–28 fx + boost Composite plan (SIB or sequential boost) | Mean ≤30 Gy | NRG vulva RT template | Vulva |
| Pelvic Bone Marrow | 45–50.4 Gy / 25–28 fx Pelvis ± nodal boost | V10 Gy ≤85.5%, V20 Gy ≤66% | NRG cervix RT template | Cervix — Definitive Chemoradiation |
| Pelvic Bone Marrow | 45–50.4 Gy / 25–28 fx Post-operative pelvis | Mean ≤27 Gy | NRG endometrial RT template | Endometrium & Cervix — Post-operative |
| Pelvic Bone Marrow | 45–50.4 Gy / 25–28 fx + boost Composite plan (SIB or sequential boost) | V10 Gy ≤85%, V20 Gy ≤70% | NRG vulva RT template | Vulva |
| Pelvic Bone Marrow | 50.4–54 Gy / 28–30 fx Dose-painted IMRT | V30 Gy <50%, V40 Gy <35%, V50 Gy <5% | RTOG 0529, NRG anal RT template | Anal Canal |
| Penile Bulb | 36.25 Gy / 5 fx To PTV (40 Gy to CTV) | V29.5 Gy <50% | PACE-B | Prostate SBRT |
| Penile Bulb | 36.25 Gy / 5 fx To PTV (40 Gy to CTV) | V36 Gy ≤0.1 cc | TROG NINJA | Prostate SBRT |
| Penile Bulb | 70 Gy / 28 fx Moderate hypofractionation | Mean dose <50 Gy | ASTRO DVH Compendium 2026 | Definitive Prostate IMRT/VMAT |
| Penile Bulb | 78–80 Gy / 39–40 fx Conventional | Mean dose <52.5 Gy | QUANTEC, RTOG 0126 | Definitive Prostate IMRT/VMAT |
| Penile Bulb | 78–80 Gy / 39–40 fx Nodes 54–60 Gy | Mean dose <52.5 Gy | QUANTEC, RTOG 0126 | Prostate + Pelvic Nodes |
| Pharyngeal Constrictors | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Mean ≤50 Gy | eviQ 5049 | Head & Neck Planning Essentials |
| Pharyngeal Constrictors | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Superior, middle and inferior: mean ≤55 Gy each | Batth 2014 | Head & Neck Planning Essentials |
| Pituitary Gland | 60 Gy / 30 fx Standard course | Mean ≤45 Gy | EPTN 2018 (Lambrecht) | High-Grade Glioma |
| Pituitary Gland | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | NPC: D0.03 cc ≤60 Gy (ideal), ≤65 Gy (acceptable) | Lee 2019 NPC guideline | Head & Neck Planning Essentials |
| Rectum | 36.25 Gy / 5 fx To PTV (40 Gy to CTV) | V38 Gy ≤0.1 cc | PACE-B | Prostate SBRT |
| Rectum | 36.25 Gy / 5 fx To PTV (40 Gy to CTV) | V29 Gy ≤20% | PACE-B | Prostate SBRT |
| Rectum | 52.5 Gy / 20 fx 2.63 Gy per fraction | V40 Gy <60% | RADICALS-HD | Post-Prostatectomy (Prostate Bed) |
| Rectum | 60 Gy / 20 fx Moderate hypofractionation | V40.8 Gy <60% | CHHiP (Dearnaley 2016), CHHiP PROs (Wilkins 2015) | Definitive Prostate IMRT/VMAT |
| Rectum | 60 Gy / 20 fx Nodes 44 Gy | V40.8 Gy <60% | CHHiP (Dearnaley 2016), CHHiP PROs (Wilkins 2015) | Prostate + Pelvic Nodes |
| Rectum | 52.5 Gy / 20 fx 2.63 Gy per fraction | V52.5 Gy <30% | RADICALS-HD | Post-Prostatectomy (Prostate Bed) |
| Rectum | 60 Gy / 20 fx Moderate hypofractionation | V60 Gy <3% | CHHiP (Dearnaley 2016), CHHiP PROs (Wilkins 2015) | Definitive Prostate IMRT/VMAT |
| Rectum | 60 Gy / 20 fx Nodes 44 Gy | V60 Gy <3% | CHHiP (Dearnaley 2016), CHHiP PROs (Wilkins 2015) | Prostate + Pelvic Nodes |
| Rectum | 45–50.4 Gy / 25–28 fx Pelvis ± nodal boost | D50% ≤45 Gy, D0.03 cc ≤50 Gy | NRG cervix RT template | Cervix — Definitive Chemoradiation |
| Rectum | 45–50.4 Gy / 25–28 fx Post-operative pelvis | V40 Gy ≤80% | NRG endometrial RT template | Endometrium & Cervix — Post-operative |
| Rectum | 45–50.4 Gy / 25–28 fx + boost Composite plan (SIB or sequential boost) | D60% ≤45 Gy, D0.03 cc ≤60 Gy | NRG vulva RT template | Vulva |
| Rectum | 68 Gy / 25 fx Nodes 45–50 Gy | V50 Gy <35% | POP-RT (toxicity) | Prostate + Pelvic Nodes |
| Rectum | 45–50.4 Gy / 25–28 fx Pelvis ± nodal boost | V40 Gy <75%, V30 Gy <95% | EMBRACE II | Cervix — Definitive Chemoradiation |
| Rectum | 68 Gy / 25 fx Nodes 45–50 Gy | V70 Gy <0.1% | POP-RT (toxicity) | Prostate + Pelvic Nodes |
| Rectum | 70 Gy / 28 fx Moderate hypofractionation | V70 Gy ≤10% | ASTRO DVH Compendium 2026 | Definitive Prostate IMRT/VMAT |
| Rectum | 70 Gy / 28 fx Moderate hypofractionation | V65 Gy ≤10% | ASTRO DVH Compendium 2026 | Definitive Prostate IMRT/VMAT |
| Rectum | 70 Gy / 28 fx Moderate hypofractionation | V40 Gy ≤35% | ASTRO DVH Compendium 2026 | Definitive Prostate IMRT/VMAT |
| Rectum | 64–66 Gy / 32–33 fx 2 Gy per fraction | V50 Gy <50% | RAVES, RADICALS-RT | Post-Prostatectomy (Prostate Bed) |
| Rectum | 64–66 Gy / 32–33 fx 2 Gy per fraction | V66 Gy <30% | RAVES, RADICALS-RT | Post-Prostatectomy (Prostate Bed) |
| Rectum | 78–80 Gy / 39–40 fx Conventional | V50 Gy <50% | ENZARAD protocol | Definitive Prostate IMRT/VMAT |
| Rectum | 78–80 Gy / 39–40 fx Nodes 54–60 Gy | V50 Gy <50% | ENZARAD protocol | Prostate + Pelvic Nodes |
| Rectum | 78–80 Gy / 39–40 fx Conventional | V70 Gy <20% | ENZARAD protocol | Definitive Prostate IMRT/VMAT |
| Rectum | 78–80 Gy / 39–40 fx Nodes 54–60 Gy | V70 Gy <20% | ENZARAD protocol | Prostate + Pelvic Nodes |
| Skin | 30–34 Gy / 1 fx Peripheral | Max dose 26 Gy | TROG SAFRON II | Lung SBRT |
| Skin | 30–34 Gy / 1 fx Peripheral | D10 cc <23 Gy | RTOG 0915 | Lung SBRT |
| Skin | 42–54 Gy / 3 fx Liver metastases | D0.1 cc ≤33 Gy | UK SABR consensus 2022 | Liver SBRT |
| Skin | 54 Gy / 3 fx Peripheral | Max dose 33 Gy | UK SABR consensus 2022 | Lung SBRT |
| Skin | 42–54 Gy / 3 fx Liver metastases | D10 cc ≤30 Gy | UK SABR consensus 2022 | Liver SBRT |
| Skin | 54 Gy / 3 fx Peripheral | D10 cc <30 Gy | UK SABR consensus 2022 | Lung SBRT |
| Skin | 27.5–60 Gy / 5 fx HCC or metastases | D0.1 cc ≤39.5 Gy | UK SABR consensus 2022 | Liver SBRT |
| Skin | 50 Gy / 5 fx Central | Max dose 32 Gy | RTOG 0813 | Lung SBRT |
| Skin | 27.5–60 Gy / 5 fx HCC or metastases | D10 cc ≤36.5 Gy | UK SABR consensus 2022 | Liver SBRT |
| Skin | 50 Gy / 5 fx Central | D10 cc <30 Gy | RTOG 0813 | Lung SBRT |
| Small Bowel | 42–54 Gy / 3 fx Liver metastases | D0.1 cc ≤25.2 Gy | UK SABR consensus 2022 | Liver SBRT |
| Small Bowel | 42–54 Gy / 3 fx Liver metastases | D5 cc ≤17.7 Gy | UK SABR consensus 2022 | Liver SBRT |
| Small Bowel | 27.5–60 Gy / 5 fx HCC or metastases | D0.1 cc ≤30 Gy (optimal), ≤35 Gy (mandatory) | UK SABR consensus 2022 | Liver SBRT |
| Small Bowel | 25 Gy / 5 fx Short course | Loops D200 cc <20 Gy, D20 cc <25 Gy | RCR rectal IMRT guidance | Rectum |
| Small Bowel | 36.25 Gy / 5 fx To PTV (40 Gy to CTV) | V30 Gy ≤1 cc | TROG NINJA | Prostate SBRT |
| Small Bowel | 27.5–60 Gy / 5 fx HCC or metastases | D10 cc ≤25 Gy | UK SABR consensus 2022 | Liver SBRT |
| Small Bowel | 25 Gy / 5 fx Short course | Bowel cavity D200 cc <23 Gy | RCR rectal IMRT guidance | Rectum |
| Small Bowel | 36.25 Gy / 5 fx To PTV (40 Gy to CTV) | V18.1 Gy ≤5 cc | PACE-B | Prostate SBRT |
| Small Bowel | 52.5 Gy / 20 fx 2.63 Gy per fraction | D1 cc <46 Gy (EQD2 50 Gy) | eviQ 4487 | Post-Prostatectomy (Prostate Bed) |
| Small Bowel | 41.4 Gy / 23 fx Preoperative | Avoid hotspots | eviQ 1861 | Esophagus & GE Junction |
| Small Bowel | 45–50.4 Gy / 25–28 fx Long course | V35 Gy <180 cc, V40 Gy <100 cc, V45 Gy <65 cc | RTOG 0822 | Rectum |
| Small Bowel | 45–50.4 Gy / 25–28 fx Pelvis ± nodal boost | Bowel space D30% ≤40 Gy, D0.03 cc ≤59.4 Gy | NRG cervix RT template | Cervix — Definitive Chemoradiation |
| Small Bowel | 45–50.4 Gy / 25–28 fx Post-operative pelvis | Bowel space V40 Gy ≤30% | NRG endometrial RT template | Endometrium & Cervix — Post-operative |
| Small Bowel | 45–50.4 Gy / 25–28 fx + boost Composite plan (SIB or sequential boost) | Bowel space D30% ≤40 Gy, D0.03 cc ≤55 Gy | NRG vulva RT template | Vulva |
| Small Bowel | 68 Gy / 25 fx Nodes 45–50 Gy | Bowel bag V45 Gy <158 cc | POP-RT (toxicity) | Prostate + Pelvic Nodes |
| Small Bowel | 45–50.4 Gy / 25–28 fx Long course | No volume ≥50 Gy | RTOG 0822 | Rectum |
| Small Bowel | 45–50.4 Gy / 25–28 fx Pelvis ± nodal boost | Bowel V40 Gy <250 cc, V30 Gy <500 cc | EMBRACE II | Cervix — Definitive Chemoradiation |
| Small Bowel | 45–50.4 Gy / 25–28 fx Post-operative pelvis | Bowel cavity V45 Gy <195 cc | QUANTEC summary | Endometrium & Cervix — Post-operative |
| Small Bowel | 45–50.4 Gy / 25–28 fx + boost Composite plan (SIB or sequential boost) | Bowel space V45 Gy ≤190 cc | NRG vulva RT template | Vulva |
| Small Bowel | 68 Gy / 25 fx Nodes 45–50 Gy | Bowel bag V60 Gy <6 cc | POP-RT (toxicity) | Prostate + Pelvic Nodes |
| Small Bowel | 45–50.4 Gy / 25–28 fx Long course | Bowel cavity V45 Gy <195 cc | QUANTEC summary | Rectum |
| Small Bowel | 50.4–54 Gy / 28–30 fx Dose-painted IMRT | Loops V30 Gy <200 cc, V35 Gy <150 cc, V45 Gy <20 cc | RTOG 0529 | Anal Canal |
| Small Bowel | 50.4 Gy / 28 fx Definitive; also 50 Gy / 25 fx | Loops max <50 Gy | eviQ 1865 | Esophagus & GE Junction |
| Small Bowel | 50.4 Gy / 28 fx 45–54 Gy / 25–30 fx | Loops V15 Gy <120 cc | QUANTEC summary | Pancreas |
| Small Bowel | 70 Gy / 28 fx Moderate hypofractionation | D0.035 cc ≤54 Gy | ASTRO DVH Compendium 2026 | Definitive Prostate IMRT/VMAT |
| Small Bowel | 50.4–54 Gy / 28–30 fx Dose-painted IMRT | Max <50 Gy | RTOG 0529 | Anal Canal |
| Small Bowel | 50.4 Gy / 28 fx 45–54 Gy / 25–30 fx | Bowel cavity V45 Gy <195 cc | QUANTEC summary | Pancreas |
| Small Bowel | 70 Gy / 28 fx Moderate hypofractionation | V40 Gy ≤1% | ASTRO DVH Compendium 2026 | Definitive Prostate IMRT/VMAT |
| Small Bowel | 64–66 Gy / 32–33 fx 2 Gy per fraction | Peritoneal cavity V45 Gy <195 cc | QUANTEC | Post-Prostatectomy (Prostate Bed) |
| Small Bowel | 78–80 Gy / 39–40 fx Conventional | Peritoneal cavity V45 Gy <195 cc | QUANTEC | Definitive Prostate IMRT/VMAT |
| Small Bowel | 78–80 Gy / 39–40 fx Nodes 54–60 Gy | Peritoneal cavity V45 Gy <195 cc | QUANTEC | Prostate + Pelvic Nodes |
| Spinal Cord | 1 fx 15–24 Gy | D0.035 cc ≤12.4 Gy (ideal), ≤14 Gy (acceptable) | UK SABR consensus 2022 | Stereotactic Radiosurgery (SRS) |
| Spinal Cord | 30–34 Gy / 1 fx Peripheral | D0.35 cc <10 Gy | RTOG 0915 | Lung SBRT |
| Spinal Cord | 30–34 Gy / 1 fx Peripheral | Max dose <12 Gy | TROG SAFRON II | Lung SBRT |
| Spinal Cord | 3 fx 24–30 Gy | D0.035 cc ≤20.3 Gy (acceptable) | UK SABR consensus 2022 | Stereotactic Radiosurgery (SRS) |
| Spinal Cord | 42–54 Gy / 3 fx Liver metastases | D0.035 cc ≤20.3 Gy | UK SABR consensus 2022 | Liver SBRT |
| Spinal Cord | 54 Gy / 3 fx Peripheral | Max dose <18 Gy | TROG CHISEL | Lung SBRT |
| Spinal Cord | 5 fx 25–35 Gy | D0.035 cc ≤25.3 Gy (acceptable) | UK SABR consensus 2022 | Stereotactic Radiosurgery (SRS) |
| Spinal Cord | 27.5–60 Gy / 5 fx HCC or metastases | D0.035 cc ≤25.3 Gy | UK SABR consensus 2022 | Liver SBRT |
| Spinal Cord | 50 Gy / 5 fx Central | D0.25 cc <22.5 Gy | RTOG 0813 | Lung SBRT |
| Spinal Cord | 50 Gy / 5 fx Central | D0.5 cc <13.5 Gy | RTOG 0813 | Lung SBRT |
| Spinal Cord | 40.05 Gy / 15 fx Short course; also 34 Gy / 10 fx and 25 Gy / 5 fx | Max <100% of prescription | eviQ 410 | High-Grade Glioma |
| Spinal Cord | 41.4 Gy / 23 fx Preoperative | Max <45 Gy | eviQ 1861 | Esophagus & GE Junction |
| Spinal Cord | 45–50 Gy / 25 fx 1.8–2 Gy per fraction | Max ≤45 Gy EQD2 (acceptable) | eviQ 1924 | Regional Nodal Irradiation |
| Spinal Cord | 45–50.4 Gy / 25–28 fx Pelvis ± nodal boost | Max <48 Gy | EMBRACE II | Cervix — Definitive Chemoradiation |
| Spinal Cord | 45–50 Gy / 25 fx 1.8–2 Gy per fraction | Max ≤40 Gy (ideal) | eviQ 1924 | Regional Nodal Irradiation |
| Spinal Cord | 50.4 Gy / 28 fx Definitive; also 50 Gy / 25 fx | Max <45 Gy | eviQ 1865 | Esophagus & GE Junction |
| Spinal Cord | 50.4 Gy / 28 fx 45–54 Gy / 25–30 fx | Max ≤45 Gy | eviQ 3581 | Pancreas |
| Spinal Cord | 60 Gy / 30 fx Standard course | Max <45 Gy | eviQ 409 | High-Grade Glioma |
| Spinal Cord | 60 Gy / 30 fx ± concurrent chemotherapy | Max dose <50 Gy | QUANTEC spinal cord | Conventional / Hypofractionated Lung RT |
| Spinal Cord | 60 Gy / 30 fx Standard course | PRV max <50 Gy | eviQ 409 | High-Grade Glioma |
| Spinal Cord | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Max ≤45 Gy (ideal), ≤50 Gy (acceptable) | QUANTEC spinal cord, Lee 2019 NPC guideline, GORTEC 2004-03, Emami 2013 | Head & Neck Planning Essentials |
| Spinal Cord | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | PRV max ≤50 Gy | RTOG 0920 | Head & Neck Planning Essentials |
| Spleen | 41.4 Gy / 23 fx Preoperative | Mean <10 Gy | RCR spleen guidance | Esophagus & GE Junction |
| Spleen | 50.4 Gy / 28 fx Definitive; also 50 Gy / 25 fx | Mean <10 Gy | RCR spleen guidance | Esophagus & GE Junction |
| Stomach | 42–54 Gy / 3 fx Liver metastases | D0.1 cc ≤22.2 Gy | UK SABR consensus 2022 | Liver SBRT |
| Stomach | 42–54 Gy / 3 fx Liver metastases | D10 cc ≤16.5 Gy | UK SABR consensus 2022 | Liver SBRT |
| Stomach | 27.5–60 Gy / 5 fx HCC or metastases | D0.1 cc ≤33 Gy (optimal), ≤35 Gy (mandatory) | UK SABR consensus 2022 | Liver SBRT |
| Stomach | 27.5–60 Gy / 5 fx HCC or metastases | D10 cc ≤25 Gy | UK SABR consensus 2022 | Liver SBRT |
| Stomach | 50.4 Gy / 28 fx 45–54 Gy / 25–30 fx | Whole organ D100% <45 Gy | QUANTEC summary | Pancreas |
| Submandibular Glands | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Mean ≤39 Gy | Murdoch-Kinch 2008 | Head & Neck Planning Essentials |
| Temporal Lobes | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | Max ≤60 Gy | Emami 2013 | Head & Neck Planning Essentials |
| Temporal Lobes | Conventional fractionation 70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op | NPC or perineural spread: D0.03 cc ≤65 Gy (T1–T2), ≤70 Gy (T3–T4) | Lee 2019 NPC guideline | Head & Neck Planning Essentials |
| Thyroid | All schedules 40.05 Gy/15 fx · 30 Gy/5 fx · 26 Gy/5 fx | Dmax ≤3% (ideal), ≤5% (acceptable) | ASTRO PBI 2023 | Partial Breast |
| Trachea & Proximal Bronchial Tree | 30–34 Gy / 1 fx Peripheral | Max dose <20.2 Gy | RTOG 0915 | Lung SBRT |
| Trachea & Proximal Bronchial Tree | 30–34 Gy / 1 fx Peripheral | D4 cc <10.5 Gy | RTOG 0915 | Lung SBRT |
| Trachea & Proximal Bronchial Tree | 54 Gy / 3 fx Peripheral | D0.5 cc <30 Gy (optimal), <32 Gy (mandatory) | UK SABR Consortium 2019 | Lung SBRT |
| Trachea & Proximal Bronchial Tree | 50 Gy / 5 fx Central | Max dose 35–38 Gy | UK SABR consensus 2022 | Lung SBRT |
| Uninvolved Ipsilateral Breast | All schedules 40.05 Gy/15 fx · 30 Gy/5 fx · 26 Gy/5 fx | V95% ≤25% (ideal), ≤40% (acceptable) | ASTRO PBI 2023 | Partial Breast |
| Uninvolved Ipsilateral Breast | All schedules 40.05 Gy/15 fx · 30 Gy/5 fx · 26 Gy/5 fx | V50% ≤50% (ideal), ≤60% (acceptable) | ASTRO PBI 2023 | Partial Breast |
| Urethra | 36.25 Gy / 5 fx To PTV (40 Gy to CTV) | V42 Gy ≤0.1 cc (acceptable) | TROG NINJA | Prostate SBRT |
| Urethra | 36.25 Gy / 5 fx To PTV (40 Gy to CTV) | V40 Gy ≤0.1 cc (ideal) | eviQ 4140 | Prostate SBRT |
No constraints listed for that combination yet. Fraction counts available: 1, 3, 5, 10, 15, 16, 20, 23, 25, 28, 30, 33, 34, 35, 39. DoseLab does not convert constraints between schedules.
Values are quoted from eviQ 1924, DEGRO 2019, eviQ 3658, RTOG 1005, eviQ 1925, SKAGEN Trial 1, eviQ 3650, DBCG HYPO 2021, eviQ 409, eviQ 410, NRG CC001, eviQ 3882, HyTEC brain (Milano 2021), eviQ 3253, eviQ 1251, eviQ 1860, eviQ 1861, eviQ 1865, eviQ 4026, eviQ 4024, eviQ 3581, QUANTEC summary, RTOG 0822, RCR rectal IMRT guidance, eviQ 1863, NRG cervix RT template, EMBRACE II, NRG endometrial RT template, NRG vulva RT template, eviQ 5049, RTOG 0920, eviQ 1871, eviQ 3389, eviQ 4018, eviQ 4487, CORSAIR, eviQ 234, ASTRO DVH Compendium 2026, eviQ 3657, eviQ 4140 and credited to the primary study each one cites. Your protocol, institutional policy and physician directive take precedence.
Other constraint sources
Protocols, consensus guidelines and reviews to consult when your schedule or organ isn't listed above.
- RTOG 0813 protocol — RTOG 0813 protocol — SBRT for centrally located NSCLC · SBRT, 5 fractions Source
- RTOG 0915 protocol — RTOG 0915 protocol — SBRT for peripheral stage I NSCLC · SBRT, 1 and 4 fractions Source
- NRG Oncology / RTOG clinical trial protocols — NRG Oncology / RTOG clinical trial protocols · Protocol-specific Source
- QUANTEC — QUANTEC — Quantitative Analyses of Normal Tissue Effects in the Clinic · Primarily conventional fractionation Source
- UK SABR consensus 2022 — UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy · SABR, multiple schedules Source
- AAPM TG-101 — Stereotactic body radiation therapy: the report of AAPM Task Group 101 · SBRT (1–5 fractions) Source
- HyTEC — HyTEC — High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic · Hypofractionated / SBRT / SRS
- Timmerman 2022 — A Story of Hypofractionation and the Table on the Wall · 1, 2, 3, 4, 5, 8, 10, 15, 20 and 30 fractions (Tables 2–11) Source